The Lymphoma and Myeloma Site Group at Princess Margaret is nationally and internationally renowned for its research on, education about and treatment of lymphoproliferative disorders. The conditions we deal with include the lymphomas (non-Hodgkin’s and Hodgkin’s lymphoma and chronic lymphocytic leukemia) and plasma cell dyscrasias, such as multiple myeloma and systemic light-chain amyloidosis.

Our group performs the most stem cell transplants for lymphoma and myeloma in Canada and receives more than 15,000 patient visits every year, making our team an authority in assessing, planning for and managing common, rare and complex lymphomas and myeloma.

Our inter-professional team of pathologists, physicians, radiation oncologists, hematologists and other medical and health care specialists works collaboratively, drawing on cutting-edge technology and treatment modalities at all stages of care. We are also recognized leaders in designing and conducting clinical trials from Phase I and Phase II studies through to international Phase III trials designed to develop new treatments and approaches and to advance best practices in the management of lymphoma and myeloma. See the Lymphoma & Myeloma Site Group research and clinical trials »

 

Collaborative Partners

Our staff members are active participants in local, national, and international collaborative partnerships, often in leadership roles. Our recent collaborators include:


Clinical Practice Guidelines

Princess Margaret Cancer Centre clinical practice guidelines are developed by multidisciplinary teams and are reflective of current evidence-based practice. These clinical practice guidelines provide information to referring institutions, regional and global partners, and assist in decision-making processes of individuals comprising multidisciplinary care teams.


Last reviewed: 2/6/2018
Last modified: 1/3/2019 10:59 AM